Efficacy and Safety of Pegylated Interferon Alfa-2a or Alfa-2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in Children and Adolescents: A Systematic Review and Meta-analysis | Zendy

Eric Druyts | Zendy; Kristian Thorlund | Zendy; Ping Wu | Zendy; Steve Kanters | Zendy; Sanni Yaya | Zendy; Curtis Cooper | Zendy; Edward J. Mills | Zendy

Open Access

Efficacy and Safety of Pegylated Interferon Alfa-2a or Alfa-2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in Children and Adolescents: A Systematic Review and Meta-analysis

Author(s) -

Eric Druyts,

Kristian Thorlund,

Ping Wu,

Steve Kanters,

Sanni Yaya,

Curtis Cooper,

Edward J. Mills

Publication year - 2012

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cis1031

Subject(s) - medicine , ribavirin , discontinuation , adverse effect , leukopenia , neutropenia , pegylated interferon , hepatitis c , meta analysis , interferon alfa , hepatitis c virus , gastroenterology , alpha interferon , immunology , chemotherapy , interferon , virus

A systematic review and meta-analysis were conducted to examine the efficacy and safety of pegylated interferon (peg-IFN) alfa-2a and peg-IFN alfa-2b plus ribavirin (RBV) in children and adolescents with chronic hepatitis C virus (HCV).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research